Clinical Trials
4
Active:1
Completed:0
Trial Phases
3 Phases
Phase 1:1
Phase 2:1
Not Applicable:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Not Applicable
2 (50.0%)Phase 1
1 (25.0%)Phase 2
1 (25.0%)A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
Not Applicable
Not yet recruiting
- Conditions
- Narcolepsy Type 1Narcolepsy Type 2Idiopathic Hypersomnia
- Interventions
- First Posted Date
- 2025-07-31
- Last Posted Date
- 2025-07-31
- Lead Sponsor
- Centessa Pharmaceuticals (UK) Limited
- Target Recruit Count
- 90
- Registration Number
- NCT07096674
- Locations
- 🇺🇸
Site Number 1, Huntersville, North Carolina, United States
A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age
Not Applicable
Recruiting
- Conditions
- Excessive Daytime Sleepiness
- Interventions
- Drug: ORX142 TabletsOther: Placebo Tablets
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Centessa Pharmaceuticals (UK) Limited
- Target Recruit Count
- 208
- Registration Number
- NCT07082829
- Locations
- 🇺🇸
Site #1, Lincoln, Nebraska, United States
A Study of ORX750 in Subjects with Narcolepsy and Idiopathic Hypersomnia
Phase 2
Not yet recruiting
- Conditions
- Narcolepsy and Idiopathic Hypersomnia
- First Posted Date
- 2025-05-12
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Centessa Pharmaceuticals UK Limited
- Target Recruit Count
- 26
- Registration Number
- 2024-518929-15-00
- Locations
- 🇮🇹
Centro Ricerche Cliniche Di Verona S.r.l., Verona, Italy
🇮🇹Azienda Ospedaliera Policlinico Universitario Tor Vergata, Rome, Italy
🇮🇹Istituto Neurologico Mediterraneo Neuromed S.p.A., Pozzilli, Italy
A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants with Advanced Solid Tumors
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Centessa Pharmaceuticals (UK) Limited
- Target Recruit Count
- 25
- Registration Number
- NCT05821777
- Locations
- 🇺🇸
Sarah Cannon Research Institute at HealthONE., Denver, Colorado, United States
🇺🇸Sarah Cannon Research Institute at Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
News
No news found